Povećana isporuka etopozida u Daltonov limfom u miševa pomoću micela s polisorbatom 20 by LAKKIREDDY HARIVARDHAN REDDY et al.
Delivery of drugs to the target sites by the use of carrier systems has recently been
the major area of drug delivery research. Incorporation of drugs into delivery carriers
prevents drugs from degradation, targets the drug to the site of action and reduces toxi-
city or side effects by modifying their in vivo distribution (1). Delivery of anticancer ag-
ents using carrier systems with an objective of enhancing their tumor concentrations has
been widely attempted (2–5). Over the years, surfactants have been of pharmaceutical
interest either as drug carriers or, more recently, as targeting systems. From the toxico-
logical point of view, non-ionic surfactants are generally regarded as safe and most suit-
143
Acta Pharm. 56 (2006) 143–155 Original research paper
Enhanced delivery of etoposide to Dalton’s lymphoma




1Drug Delivery Research Laboratory
Center of Relevance and Excellence in
NDDS, Pharmacy Department, G.H. Patel
Building, Donor’s Plaza, Fatehgunj
Baroda-390002, Gujarat, India
2Division of Radiopharmaceuticals and
Radiation Biology, Institute of Nuclear
Medicine and Allied Sciences, Brig. S.K.
Mazumdar Road, Delhi 110 054, India
Accepted November 11, 2005
The study evaluates the possibility of enhancing uptake
of etoposide (topoisomerase II inhibitor) by tumor when
delivered through polysorbate 20 micelles. The micelle
formation was ascertained by determining the critical
micellar concentration (CMC) with a du Nouy ring ten-
siometer and by size measurement using dynamic light
scattering. Addition of 5% ethanol decreased the CMC of
Polysorbate 20 (from 5.0 x 10–5 to 4.54 x 10–5 mol L–1).
Etoposide (ET) and etoposide loaded polysorbate 20 mi-
celles (EPM) were radiolabeled with 99mTc by the reduc-
tion method using stannous chloride. Labeling parame-
ters were optimized to obtain high labeling efficiency. The
diethylenetriaminepentaacetic acid and cysteine challen-
ge tests showed very low transchelation of 99mTc-ET and
99mTc-EPM complexes indicating their in vitro stability. The
complexes also exhibited serum stability assessed by as-
cending thin layer chromatography. Subcutaneous injec-
tion of EPM resulted in significantly higher tumor up-
take ( 100 folds compared to ET 6 h post injection) (p <
0.001) and prolonged tumor retention. Tumor uptake was
also confirmed by gamma imaging studies. EPM exhib-
ited relatively high brain concentrations ( 7 fold 24 h
post injection) compared to ET, suggesting the potential
use of EPM in the treatment of brain malignancies.
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able for pharmaceutical formulations (6). The very small size of micelles (< 100 nm) pre-
vents uptake by the reticuloendothelial system and facilitates their extravasation at leaky
sites of capillaries, leading to passive accumulation in tumor tissues and penetration into
cells (6). The use of polysorbates (non-ionic surfactants) in drug delivery by parenteral
route is well documented (7–9).
Major determinants of drug delivery to tumors are the tissue structure, tissue com-
position and tumor cell density (10). Both systemic and regional chemotherapy are used
in the management of cancer. Following intravenous (i.v.) administration, the drug de-
livery to tumor involves various processes such as distribution through vascular space,
transport across microvessel walls, and diffusion through interstitial space in the tumor
tissue. In local chemotherapy such as after subcutaneous administration, the drug trans-
port into tumors is mainly by diffusion through the interstitial space (10). Effective an-
titumor activity of subcutaneously administered 1,3-bis(2-chloroethyl)-1-nitrosourea and
paclitaxel implants in human brain tumor xenografts developed after subcutaneous in-
oculation in nude mice has been reported by Vogelhuber et al. (11).
Radiolabeling of drugs and their carriers to study their in vivo distribution has been
widely attempted. Our recent reports showed successful formation of stable 99mTc la-
beled drug and liposome/nanoparticle complexes and their use in biodistribution stud-
ies (12, 13).
Etoposide (ET) is an anticancer agent used in the treatment of a variety of malignan-
cies and has been demonstrated to be effective in the treatment of small cell lung carci-
noma, brain stem gliomas, malignant lymphoma and ovarian cancer. It acts by inhibition
of topoisomerase II and activation of oxidation/reduction reactions to produce deriva-
tives that bind directly to DNA and cause DNA damage (14, 15). The present study de-
scribes our attempt to enhance the delivery of etoposide to Dalton’s lymphoma solid tumor
in mice by incorporating etoposide into polysorbate 20 micelles. Polysorbate 20 micelles
loaded with etoposide (EPM) were prepared, characterized and radiolabeled with 99mTc.
The in vitro stability of radiolabeled complexes was examined by the diethylenetriamine-
pentaacetic acid (DTPA) and cysteine challenge tests; their stability in serum was estab-
lished as well. These radiolabeled complexes were subcutaneously injected below the
tumor region and the biodistribution and tumor transport in Dalton’s lymphoma tumor
bearing mice were studied.
EXPERIMENTAL
Chemicals
Etoposide was a gift sample obtained from Dabur Research Center (India) and Cipla
Limited (India). Polysorbate 20 was purchased from Merck Limited (India). Diethylene-
triaminepentaacetic acid and cysteine were obtained from Sigma Chemical Co. (USA).
Stannous chloride was purchased from Qualigens (India). Sodium pertechnetate eluted
from molybdenum-99 by solvent extraction was procured from the Regional Center for
Radiopharmaceutical Division (Northern region), Board of Radiation and Isotope Tech-
nology (BRIT), India. All other chemicals used in the study were of analytical grade.
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Etoposide-loaded polysorbate 20 micelles
Etoposide-loaded polysorbate 20 micelles were prepared by dissolving etoposide (2
mg mL–1) in 10% aqueous polysorbate 20 solution containing 5% ethanol. The mixture
was slightly warmed to clarify the solution.
Characterization of micelles
The micelles were characterized by critical micellar concentration (CMC) measure-
ments and size determination.
Determination of CMC of polysorbate 20
Determination of CMC of polysorbate 20 micelles was performed by the surface
tension measurement by the ring method (16) using a du Nouy ring tensiometer (S. C.
Dey & Co., India) at 30 ± 1 °C. The temperature was maintained by circulating thermos-
tated water through a jacketed vessel containing the solution. The concentration was
varied by adding aliquots of the stock surfactant solution of known concentration to a
known volume of solution in the vessel using a Hamilton microsyringe. The ring was
cleaned by heating in alcohol flame. The measured surface tension values were plotted
as a function of the logarithm of surfactant concentration and the CMC was estimated
from the break-point in the resultant curve. Reproducibility of the surface tension vs.
concentration curve was checked by triplicate runs.
Determination of the size of micelles
The micellar size was determined in a particle size analyzer (Malvern Zetasizer 3000HSA
Particle size analyzer, Malvern Instruments, UK) by the injection method. The micellar
preparation was injected into the injection port of the particle size analyzer and the aver-
age mean diameter was estimated.
Radiolabeling of etoposide and polysorbate 20 micelles
ET and EPM were labeled with technetium (99mTc) after reduction with stannous
chloride similarly to the previously reported methods (17, 18). Briefly, 2 mCi pertech-
netate (TcO4–) was reduced with 20 µg SnCl2  2 H2O for both ET and EPM (in 10% ace-
tic acid) and pH was adjusted to 6.5 with 0.5 mol L–1 sodium bicarbonate. The volume of
the reaction medium was 0.5 mL. ET (2 mg mL–1) and/or EPM (equivalent to 2 mg mL–1
of ET) was added and incubated at room temperature for 10 min. Quality control was
performed as for the method described earlier (17). The labeling efficiency of ET and
EPM was determined by ascending thin layer chromatography using silica gel coated fi-
ber sheets (Gelman Sciences Inc., USA). Ascending thin layer chromatography was per-
formed by spotting 2–3 L on an instant thin layer chromatography (ITLC) strip and de-
veloped using acetone as the mobile phase. The strip was cut into two halves and the
radioactivity in each half was determined with a well type gamma ray spectrometer
(Type GRS23C, Electronics Corporation of India Limited, India). Free pertechnetate (Rf =
0.9–1.0) migrates to the top portion of the ITLC strip, leaving the reduced/hydrolyzed
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99mTc along with the labeled complex at the bottom. Incorporation of excess of stannous
chloride for reduction of 99mTc may lead to the formation of undesirable radiocolloids.
Colloids formation was determined in pyridine/acetic acid/water (3:5:1.5). In the case
of acetone as the mobile phase (developed for determining the labeling efficiency), only
free pertechnetate moves with the solvent front leaving the labeled complex (plus radio-
colloids) at the bottom. The mobile phase pyridine/acetic acid/water (3:5:1.5) separates
radiocolloids from the labeled complex and free pertechnetate, and allows the labeled
complex to move with the solvent front, with radiocolloids remaining at the bottom. The
net amount of 99mTc-ET or 99mTc-EPM was calculated by subtracting the migration with
the solvent front using acetone from that using pyridine/acetic acid/water mixture.
Stability of the 99mTc labeled complexes
Stability of the 99mTc labeled complexes of ET and EPM was determined in vitro in
freshly collected human serum by the ascending TLC technique. The labeled complex
(0.1 mL) was incubated with human serum (0.4 mL) at 37 °C. The stability test was per-
formed by determining the changes in labeling efficiency by subjecting the samples to
ITLC at regular intervals up to 24 h and analyzing the chromatograms in a gamma ray
spectrometer.
DTPA and cysteine challenge
In vitro stability studies of 99mTc labeled complexes were performed with DTPA and
cysteine as previously reported (19). Briefly, fresh solutions of DTPA and cysteine (10, 30
and 50 mmol L–1) were prepared in 0.9% saline. 500 µL of the labeled preparation was
incubated with different concentrations of DTPA and cysteine for 1 h at 37 °C. 500 µL of
0.9% saline served as control. The effect of DTPA and cysteine on the labeling efficiency
of complexes was measured by ITLC-silica gel strips using acetone as the mobile phase.
In this system, 99mTc–ET and 99mTc–EPM remain at the start (Rf = 0.0), while pertech-
netate (Rf = 0.9–1.0) and all known chemical forms of 99mTc-DTPA and 99mTc–cysteine
complexes migrate (Rf = 0.7–1.0). After developing, each paper was cut into two halves
and each half was counted for radioactivity in the gamma ray spectrometer.
Animals
Balb/c mice of either sex weighing about 25–30 g were used in the study. The mice
were housed in cages and were provided with water and standard mouse food (Liptin,
India) ad libitum. All animal experiments in this study were approved by the Social Jus-
tice & Empowerment Committee for the purpose of control and supervision of experi-
ments on animals (CPCSEA), Government of India, New Delhi.
Tumor implantation in mice
Dalton’s lymphoma tumor cells maintained in the ascites form in the peritoneum of
Balb/c mice by serial weekly passage were subcutaneously inoculated (5 x 106 cells per
mouse) into the right hind leg of Balb/c mice (7–8 weeks old). After 8–10 days, a palpable
tumor in the volume range of 0.9 ± 0.1 cm3 was observed and used for further studies.
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Biodistribution study
99mTc-ET and 99mTc-EPM were subcutaneously injected into tumor bearing Balb/c
mice. Two groups containing nine tumor bearing mice each, one for the 99mTc-ET and
the other for 99mTc-EPM were used in the study. The biodistribution study was perform-
ed 1, 6 and 24 h post injection. At these time intervals, blood was collected by cardiac
puncture, animals were sacrificed and their organs were isolated. The organs were then
weighed and measured for radioactivity using a gamma ray spectrometer. The radioac-
tivity was interpreted as % injected dose (% ID) per gram of organ/tissue. To correct for
physical decay of radiolabel and to calculate radiopharmaceutical uptake in each organ
as a fraction of the injected dose, aliquots of the injectate containing 2% of the injected
dose were counted simultaneously at each time point.
Tumor imaging by gamma scintigraphy
100 µCi of the 99mTc-EPM was administered subcutaneously below the tumor re-
gion on the right hind leg. 24 h after injection, the mice were fixed on an animal fixing
tray board and imaging was performed with a Single Photon Emission Computed To-
mography (SPECT, LC 75-005, Diacam, Siemens, USA) gamma camera.
Statistical analysis
Statistical comparisons of the experimental results were performed by Student’s t
test at 0.05 and 0.001 significance levels.
RESULTS AND DISCUSSION
Polyoxyethylene surfactants possess a hydrophobic core, which can incorporate hy-
drophobic drugs (20). ET being a hydrophobic drug gets incorporated into the inner hy-
drophobic portion of micelles. Polysorbate 20 spontaneously forms micelles above its
CMC. At very low concentrations, the surfactant molecules remain as single chains. But,
as the concentration reaches a critical value (i.e., critical micellar concentration), the po-
lymer chains associate to form micelles such that the hydrophilic portion projects into
the aqueous phase and hydrophobic portion moves towards the inner core. At CMC, the
micelle core incorporates more solvent and they appear as loose aggregates with a size
larger than the micelles formed at high surfactant concentrations (21). At concentrations
above the CMC, the equilibrium favors the formation of micelles with a smaller size as
they adopt low energy configuration (22). Fig. 1 represents the determination of CMC of
polysorbate 20 in both pure water and water containing 5% ethanol. The CMC of po-
lysorbate 20 in pure water at 30 °C is 5.0 x 10–5 mol L–1, which is in good agreement with
the earlier reports (23). Reduced CMC of polysorbate 20 was found (4.54 x 10–5 mol L–1)
in water containing 5% ethanol, indicating the effect of ethanol on CMC of polysorbate
20. The size of the micelles was determined by dynamic light scattering, and was found
to be (mean ± SD, n = 3) 40.0 nm ± 13.2 nm (range 28–55 nm). Polar organic compounds
such as alcohols were reported to affect the CMC by being incorporated into the micelles
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(24). This is probably due to the adsorption of ethanol mainly in the outer portion of the
micelle, close to the water-micelle interface (24). Ethanol forms hydrogen bonds with
water, and hydrogen bonding helps counterbalance the lateral pressure tending to push
the additive (ethanol) into the interior of the micelle resulting in a decrease in CMC. The
concentration of polysorbate 20 used in the formulation of drug loaded micelles is about
100 times higher than the CMC, indicating its existence in the form of micelles. Etopo-
side being a hydrophobic drug gets incorporated into the inner hydrophobic portion of
micelles. The EPM remained clear upon storage, and the absence of drug precipitate and
a minor increase in size even after one week of storage (43.0 ± 24.8 nm, range 33–62 nm,
n = 3) indicate the stability of drug loaded micelles.
Radiolabeling of etoposide and EPM
ET and EPM were radiolabeled with 99mTc with high labeling efficiency. The per-
technetate existing in its seventh oxidative state was reduced to its lower valence (fourth)
state by stannous chloride and the pH adjusted to 6.5 before addition of ET or EPM. The
amount of stannous chloride played an important role in the labeling process. The influ-
ence of stannous chloride on labeling efficiency and formation of radiocolloids is shown
in Table I. The optimum amount of stannous chloride resulted in high labeling efficiency
and a small amount of radiocolloids. The volume of the reaction mixture was kept con-
stant for both ET and EPM. Smaller amount of SnCl2, led to poor labeling efficiency and
its larger amount, led to greater formation of undesirable radiocolloids. These radiocol-
loids distribute extensively to the organs of the reticuloendothelial system due to their
macrophage uptake.
In vitro stability of labeled complexes
The in vitro stability of radiolabeled complexes needs to be confirmed before their
use for biodistribution studies. Determination of the stability of radiolabeled complexes
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Fig. 1. Plot of surface tension () vs. log c of polysorbate 20 in pure water and water containing
5% ethanol (mean of 3 determinations).
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Table I. Influence of the amount of stannous chloride on the labeling efficiency of etoposide




Labeled (%) Colloids (%) Free (%) Labeled (%) Colloids (%) Free (%)
5 80.24 ± 1.20 0.45 ± 0.34 19.31 ± 1.85 84.61 ± 2.15 0.45 ± 0.56 14.94 ± 1.80
10 88.76 ± 1.34 0.48 ± 0.54 1.76 ± 0.12 92.17 ± 1.45 0.56 ± 0.75 8.39 ± 1.25
20 99.28 ± 2.05 0.68 ± 0.31 0.04 ± 0.42 98.78 ± 1.78 0.83 ± 1.05 0.39 ± 1.12
25 98.25 ± 1.54 1.18 ± 0.64 0.57 ± 0.34 96.82 ± 2.34 2.38 ± 0.88 0.80 ± 1.56
50 96.78 ± 1.42 3.01 ± 1.15 0.21 ± 0.86 94.16 ± 1.64 4.98 ± 1.25 0.86 ± 0.98
a Each value is the mean of three experiments ± SD.
b c(Sn2+) = 2.4  10–8 – 2.4  10–7 mol L–1.
c ET – etoposide, PM – etoposide loaded polysorbate 20 micelles.
Table II. Stability of 99mTc labeled complexes of etoposide and
etoposide loaded polysorbate 20 micelles in human seruma
Radiolabeling (%)
Time (h) ETb EPMb
99.28 ± 1.58 98.78 ± 1.68
0.25 99.20 ± 1.98 98.80 ± 2.15
0.5 99.22 ± 1.58 98.71 ± 1.42
1 99.10 ± 1.87 98.60 ± 2.25
2 99.01 ± 1.25 98.42 ± 1.38
4 98.94 ± 2.15 98.12 ± 1.63
8 98.78 ± 1.75 97.96 ± 1.97
24 97.79 ± 2.23 97.22 ± 2.53
a Each value is the mean ± SD of three experiments.
b ET – etoposide, EPM – etoposide loaded polysorbate 20 micelles.
Fig. 2. In vitro stability of 99mTc labeled complexes of etoposide and etoposide loaded polysorbate
20 micelles by: a) DTPA challenge test; b) cysteine challenge test. Each data point is the mean ± SD
of 3 experiments. ET – etoposide, EPM – etoposide loaded polysorbate 20 micelles.
a) b)
in serum in vitro is an important parameter because the serum contains proteins which
may chelate and bind to 99mTc (termed transchelation), disturbing the stability of 99mTc-
-labeled complexes. The stability of 99mTc-labeled complexes in serum also supports
their stability in a biological environment upon administration to the body. 99mTc-label-
ed complexes of ET and EPM were challenged with 10, 30 and 50 mmol L–1 of DTPA and
cysteine to test the strength of binding and stability. Challenge studies demonstrated
that the labeling efficiency of the complexes did not alter much in the presence of DTPA
(Fig. 2a) and cysteine (Fig. 2b). Even at 50 mmol L–1 concentration of DTPA and cysteine,
the transchelation was found to be less than 5% indicating a high degree of stability of
the radiolabeled complexes. The data (Table II) demonstrated the stability of 99mTc-ET
and 99mTc-EPM in serum determined up to 24 h, indicating their use as markers for bio-
distribution studies.
Biodistribution study
Dalton’s lymphoma is a lymphoma of T-cell type. In the case of Dalton’s lympho-
ma, the regional lymph nodes are affected by cancer. According to Muranishi and co-
workers (25) and Takahashi (26), tumor cells that have detached from the tissue or have
invaded a lymphatic vessel would be trapped in the meshwork of a lymph node. Earlier
studies showed that the optimal size range of colloidal species (such as 99mTc-sulphur
colloid, 198Au colloid, etc.) for better lymphatic drainage was 10–50 nm (27). The bio-
distribution of subcutaneously injected 99mTc labeled complexes of ET and EPM was de-
termined in Balb/c mice 1, 6 and 24 h post injection (Table III) below the tumor region in
the right hind limb of mice. EPM uptake was low initially (1 h post injection) in the or-
gans such as liver, lung and spleen, and increased slightly 6 h post injection. This sug-
gests a slower clearance of micelles from the site of injection and also after being concen-
trated in the tumor. The relatively low concentration of micelles in the liver throughout
the study indicates reduced phagocytosis. The EPM concentration in spleen and lung
24 h post injection was significantly higher than ET (p < 0.001). Concentrations of both
ET and EPM in the kidney decreased with time. However, the EPM concentration in the
kidney was significantly lower than ET. The uptake of EPM by bones was higher than
ET throughout the experiment. However, the concentrations were significantly higher
only 6 h post injection. The brain uptake of EPM increased 6 h post injection and re-
mained higher even 24 h post injection (7 fold higher than ET). This is in good agree-
ment with earlier reports on high brain uptake of polysorbate 80 coated systems (28–30).
The possible mechanisms suggested for enhanced brain penetration of the polysorbate
coated systems are endocytosis, opening of the tight endothelial junctions between the
brain endothelial cells, and the third possibility is the inhibition of P-glycoprotein efflux
pump responsible for multi-drug resistance, which is a major obstacle to cancer chemo-
therapy. This observation could be extended to confirm the higher brain transport of
EPM after intravenous administration and its possible use in the treatment of brain ma-
lignancies (14). EPM showed greater muscle concentrations 24 h post injection. The tu-
mor uptake of EPM was significantly higher than that of ET (2.06% ID of ET, 10.3% ID of
EPM after 1 h (p < 0.001) and 0.08% ID of ET, 4.18% ID of EPM remained in tumor 24 h
post injection (p < 0.001)) (Fig. 3) indicating rapid diffusion of EPM into tumor and prolong-
ed tumor retention. EPM showed a 102-fold increase in tumor concentration compared
to ET 6 h post injection. This may be attributed to the smaller size of micelles aiding
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their infiltration into tumor and resulting in high tumor transfer. Increase in membrane
permeability by EPM could also be a contributing factor for high tumor uptake. The hy-
drophilic surface of EPM might have contributed to the high tumor uptake as well. An
earlier report on extensive localization of hydrophilic polymer Poloxamine 904 coated
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Fig. 3. Tumor concentrations of 99mTc labeled complex-
es of etoposide and etoposide loaded polysorbate 20
micelles. Each data point is the mean ± SD of 3 ex-
periments. ET – etoposide, EPM – etoposide loaded
polysorbate 20 micelles.
Table III. Biodistribution of 99mTc labeled complexes of ET and EPM after subcutaneous injection in
Dalton’s lymphoma tumor bearing mice
Injected dose per gram of organ/tissue (%)a,b
Organ/tissue
1 h 6 h 24 h
ET EPM ET EPM ET EPM
Blood 0.13 ± 0.01 0.13 ± 0.01 0.19 ± 0.01 0.10 ± 0.01 0.08 ± 0.01 0.22 ± 0.01d
Heart 0.14 ± 0.02 0.08 ± 0.01 0.08 ± 0.01 0.06 ± 0.01 0.08 ± 0.01 0.30 ± 0.01
Liver 0.30 ± 0.05 0.09 ± 0.01d 0.21 ± 0.05 0.10 ± 0.02d 0.28 ± 0.03 0.19 ± 0.02d
Lung 0.18 ± 0.03 0.08 ± 0.01d 0.14 ± 0.03 0.10 ± 0.02d 0.08 ± 0.01 0.36 ± 0.05d
Stomach 0.28 ± 0.03 0.36 ± 0.05 0.25 ± 0.03 0.16 ± 0.02 0.16 ± 0.02 0.26 ± 0.04
Intestine 0.24 ± 0.04 0.08 ± 0.03 0.38 ± 0.05 0.23 ± 0.03 0.59 ± 0.03 0.06 ± 0.01
Spleen 0.05 ± 0.01 0.03 ± 0.01e 0.04 ± 0.01 0.06 ± 0.01 0.07 ± 0.01 0.71 ± 0.06d
Kidney 1.40 ± 0.09 0.66 ± 0.06d 0.91 ± 0.08 0.55 ± 0.03d 0.68 ± 0.04 0.42 ± 0.05d
Musclec 0.05 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 0.12 ± 0.01d
Bone 0.09 ± 0.01 0.11 ± 0.03 0.08 ± 0.01 0.26 ± 0.05d 0.18 ± 0.01 0.36 ± 0.04d
Brain 0.02 ± 0.02 0.01 ± 0.01 0.01 ± 0.01 0.04 ± 0.02d 0.01 ± 0.01 0.07 ± 0.03d
a The animals were subcutaneously injected with 100 µCi of the 99mTc labeled complexes of etoposide and
etoposide loaded polysorbate 20 micellar formulation, and were sacrificed at 1, 6 and 24 h post injection. Ra-
dioactivity was counted in each organ and expressed as % injected dose per gram of organ/tissue.
b Each value is the mean ± SEM of 3 animals.
c The muscle contralateral to the tumor inoculated thigh was collected for the study.
Significant difference between ET and EPM: d p < 0.001, e p < 0.05.
ET – etoposide, EPM – etoposide loaded polysorbate 20 micelles.
polystyrene microspheres (60 nm) in the regional lymph nodes after local administration
in the foot pad in rats supports our finding (31). The gamma scintigraphic image of mice
taken 24 h post injection of EPM clearly demonstrated prolonged tumor retention (Fig.
4). A previous report on the subcutaneously administered liposomal bupivacaine in the
local region resulting in wound infiltration with increased duration of analgesia and
slow release plasma profiles compared to the standard aqueous formulation supports
our observation of significantly higher tumor uptake after subcutaneous (s.c.) injection
below the tumor region (32). Distribution of EPM to femur bone in the tumor region was
relatively higher than that of ET after 1 h and significantly higher after 6 h (14.5 folds)
and 24 h (1.8 folds) post injection (Fig. 5). The 99mTc separated from the labeled complex
inside the body concentrate mainly in the stomach, intestine and the thyroid. A very low
recovery of 99mTC from stomach and intestine indicates the intactness of the labeled
complexes inside the body and their in vivo stability. From the biodistribution data it is
evident that the subcutaneous injection of EPM below the tumor region resulted in long
lasting tumor concentrations, which would lead to prolonged exposure of tumor tissue
to etoposide, resulting in a stronger antitumor effect and tumor regression.
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Fig. 4. Gamma scintigraphic image of Dalton’s lymphoma
tumor bearing mice 24 h post subcutaneous injection of
99mTc-etoposide loaded micellar formulation. The circle
portion indicates high tumor uptake and prolonged tumor
retention of etoposide loaded polysorbate 20 micelles in





















Fig. 5. Concentrations of 99mTc labeled complexes
of etoposide and etoposide loaded polysorbate
20 micelles in femur bone in the tumor region.
Each data point is the mean ± SD of 3 experiments.
ET – etoposide, EPM – etoposide loaded poly-
sorbate 20 micelles.
CONCLUSIONS
Administration of the etoposide loaded polysorbate 20 micellar formulation by sub-
cutaneous injection significantly enhanced the tumor uptake. The micellar encapsulated
etoposide also exhibited prolonged tumor retention. The relatively high brain concentra-
tions of EPM compared to free etoposide indicate its potential use in the treatment of
brain malignancies. The study points to the advantage of polysorbate 20 micelles in de-
livering etoposide to tumors at high concentrations for a prolonged time, which is ex-
pected to lead to enhanced antitumor activity and tumor regression. Though the
micellar formulation of etoposide showed good tumor uptake, its detailed toxicity need
to be evaluated before clinical trials on human patients are initiated.
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S A @ E T A K
Pove}ana isporuka etopozida u Daltonov limfom u mi{eva
pomo}u micela s polisorbatom 20
LAKKIREDDY HARIVARDHAN REDDY, RAKESH KUMAR SHARMA i RAYASA RAMACHANDRA MURTHY
U radu je prou~avan ulazak etopozida (inhibitora topoizomeraze II) u tumorsko tki-
vo iz micela s polisorbatom 20. Oblikovanje micela je potvr|eno odre|ivanjem kriti~ne
micelarne koncentracije (CMC) pomo}u du Nouy kru`nog tenziometra i mjerenjem veli-
~ine ~estica metodom rasapa svjetlosti. Dodatak 5% etanola smanjuje CMC polisorbata
20 (od 5,0 x 10–5 do 4,54 x 10–5 mol L–1). Etoposid (ET) i micele etoposida s polisorbatom
20 (EPM) obilje`ene su radioizotopom 99mTc redukcijom pomo}u kositrova klorida. Pa-
rameteri markiranja su optimirani. Testovi s dietilentriaminpentaoctenom kiselinom i
cisteinom pokazali su vrlo nisko transkeliranje 99mTc-ET i 99mTc-EPM kompleksa, {to
ukazuje na njihovu stabilnost u uvjetima in vitro. Uzlaznom tankoslojnom kromatogra-
fijom dokazana je i stabilnost kompleksa u serumu. Nakon subkutane primjene EPM
isporuka etopozida u tumorsko tkivo bila je zna~ajno ve}a ( 100 puta u odnosu na ET 6
h poslije injiciranja) (p < 0,001), a dokazano je i produljeno zadr`avanje EPM u tumoru.
Ulazak u tumor potvr|en je i gama analizom slike. EPM je postigao relativno visoku
koncentraciju u mozgu u usporedbi s ET ( 7 puta ve}u 24 h poslije injiciranja), zbog
~ega bi se potencijalno mogao upotrijebiti u terapiji malignih tumora mozga.
Klju~ne rije~i: etopozid, micele s polisorbatom, isporuka lijeka, obilje`avanje radioizotopom,
biodistribucija, transport u tumor
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